RELATIVITY-073 is a randomised phase II study investigating relatinib (anti-LAG3) and nivolumab vs. nivolumab monotherapy in patients with advanced HCC who have progressed on first-line TKI therapy and are immunotherapy-naive (NCT04567615). Here, LAG3 is linked to hepatocellular carcinoma.